These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 37960806)

  • 41. [Expressions and clinical significance of urokinase-type activator (uPA) and uPA receptor (uPAR) in laryngeal squamous cell carcinoma].
    Wang D; Wang T
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2005 Jun; 19(12):529-31. PubMed ID: 16176001
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma - a 7.5-year follow-up study.
    Jelisavac-Cosic S; Sirotkovic-Skerlev M; Kulic A; Jakic-Razumovic J; Kovac Z; Vrbanec D
    Tumori; 2011; 97(4):532-9. PubMed ID: 21989445
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Urokinase-type plasminogen activator receptor in gastric cancer: tissue expression and prognostic role.
    Plebani M; Herszènyi L; Carraro P; De Paoli M; Roveroni G; Cardin R; Tulassay Z; Naccarato R; Farinati F
    Clin Exp Metastasis; 1997 Jul; 15(4):418-25. PubMed ID: 9219730
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The urokinase-type plasminogen activator and inhibitors in resectable lung adenocarcinoma.
    Zhu C; Jiang L; Xu J; Ren A; Ju F; Shu Y
    Pathol Res Pract; 2020 Apr; 216(4):152885. PubMed ID: 32113794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prognostic Impact of Preoperative Plasma Levels of Urokinase Plasminogen Activator Proteins on Disease Outcomes after Radical Cystectomy.
    Schuettfort VM; Pradere B; D'Andrea D; Grossmann NC; Quhal F; Mostafaei H; Laukhtina E; Mori K; Rink M; Karakiewicz PI; Motlagh RS; Katayama S; Lotan Y; Scherr D; Abufaraj M; Fajkovica H; Compérat E; Enikeev D; Shariat SF
    J Urol; 2021 Nov; 206(5):1122-1131. PubMed ID: 34181469
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Study on the correlation between combined detection of RACK1 and M2/M1 in oral squamous cell carcinoma and prognosis of the patients].
    Zhu J; Xu T; Song DH; Wu SB
    Shanghai Kou Qiang Yi Xue; 2022 Oct; 31(5):517-522. PubMed ID: 36758601
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Both the cytosols and detergent extracts of breast cancer tissues are suited to evaluate the prognostic impact of the urokinase-type plasminogen activator and its inhibitor, plasminogen activator inhibitor type 1.
    Jänicke F; Pache L; Schmitt M; Ulm K; Thomssen C; Prechtl A; Graeff H
    Cancer Res; 1994 May; 54(10):2527-30. PubMed ID: 8168072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues.
    Costantini V; Sidoni A; Deveglia R; Cazzato OA; Bellezza G; Ferri I; Bucciarelli E; Nenci GG
    Cancer; 1996 Mar; 77(6):1079-88. PubMed ID: 8635127
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Monitoring of chemotherapy successfulness of platina/taxol chemotherapy protocol by using determination of serum urokinase plasminogen activator (uPA) and soluble urokinase plasminogen activator receptor (suPAR) in patients with ovarian carcinoma FIGO II and III stage.
    Ljuca D; Fatusić Z; Iljazović E; Ahmetović B
    Bosn J Basic Med Sci; 2007 May; 7(2):111-6. PubMed ID: 17489744
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Larger and more invasive colorectal carcinoma contains larger amounts of plasminogen activator inhibitor type 1 and its relative ratio over urokinase receptor correlates well with tumor size.
    Abe J; Urano T; Konno H; Erhan Y; Tanaka T; Nishino N; Takada A; Nakamura S
    Cancer; 1999 Dec; 86(12):2602-11. PubMed ID: 10594855
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Urokinase-type plasminogen activator, its inhibitor, and its receptor in patients with upper urinary tract carcinoma.
    Nakanishi K; Kawai T; Torikata C; Aurues T; Ikeda T
    Cancer; 1998 Feb; 82(4):724-32. PubMed ID: 9477106
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy.
    Abufaraj M; Kimura S; Haitel A; Iwata T; Isleem U; D'Andrea D; Soria F; Mori K; Rink M; Bensalah K; Rouprêt M; Margulis V; Briganti A; Karakiewicz PI; Shariat SF
    Urol Oncol; 2020 Aug; 38(8):685.e17-685.e25. PubMed ID: 32381392
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Urokinase-type plasminogen activator expression and proliferation stimulation in head and neck squamous cell carcinoma in vitro and in situ.
    Schmidt M; Grünsfelder P
    Arch Otolaryngol Head Neck Surg; 2001 Jun; 127(6):679-82. PubMed ID: 11405867
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High expression of GPNMB predicts poor prognosis in head and neck squamous cell carcinoma.
    Li H; Xiao Y; Wu CC; Yang LL; Cao LY; Chen DR; Zhou JJ; Zhang WF; Sun ZJ
    Histol Histopathol; 2019 Jul; 34(7):803-810. PubMed ID: 30632601
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasminogen activator inhibitor-1 as a measure of vascular remodelling in breast cancer.
    Fox SB; Taylor M; Grøndahl-Hansen J; Kakolyris S; Gatter KC; Harris AL
    J Pathol; 2001 Sep; 195(2):236-43. PubMed ID: 11592104
    [TBL] [Abstract][Full Text] [Related]  

  • 58. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis.
    Grøndahl-Hansen J; Christensen IJ; Rosenquist C; Brünner N; Mouridsen HT; Danø K; Blichert-Toft M
    Cancer Res; 1993 Jun; 53(11):2513-21. PubMed ID: 8388317
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Urokinase-type plasminogen activator (uPA) and its receptor (CD87): a new target in tumor invasion and metastasis.
    Schmitt M; Wilhelm O; Jänicke F; Magdolen V; Reuning U; Ohi H; Moniwa N; Kobayashi H; Weidle U; Graeff H
    J Obstet Gynaecol (Tokyo 1995); 1995 Apr; 21(2):151-65. PubMed ID: 8556577
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer.
    Ji F; Chen YL; Jin EY; Wang WL; Yang ZL; Li YM
    World J Gastroenterol; 2005 Jun; 11(21):3222-6. PubMed ID: 15929171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.